Bioanalytical Strategies for PK Analysis of ADC Therapeutics using LCMS & LCHRMS

ADCs (Antibody Drug Conjugates) combines the best of two modalities, toxic efficacy, and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Here we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*